Imbruvica and Pulmonary aspergilloma (mycetoma) - a phase IV clinical study of FDA data


Pulmonary aspergilloma (mycetoma) is reported only by a few people who take Imbruvica.

The phase IV clinical study analyzes which people take Imbruvica and have Pulmonary aspergilloma (mycetoma). It is created by eHealthMe based on reports of 50,071 people who have side effects while taking Imbruvica from the FDA, and is updated regularly.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Jan, 29, 2023

50,071 people reported to have side effects when taking Imbruvica.
Among them, 4 people (0.01%) have Pulmonary aspergilloma (mycetoma).

What is Imbruvica?

Imbruvica has active ingredients of ibrutinib. It is often used in chronic lymphocytic leukemia (cll). eHealthMe is studying from 50,136 Imbruvica users for its effectiveness, alternative drugs and more.

What is Pulmonary aspergilloma (mycetoma)?

Pulmonary aspergilloma (mycetoma) (mass caused by a fungal infection that usually grows in lung) is found to be associated with 437 drugs and 217 conditions by eHealthMe.

Number of Imbruvica and Pulmonary aspergilloma (mycetoma) reports submitted per year:

Could Imbruvica cause Pulmonary aspergilloma (mycetoma)?

Gender of people who have Pulmonary aspergilloma (mycetoma) when taking Imbruvica *:

  • female: 0.0 %
  • male: 100 %

Age of people who have Pulmonary aspergilloma (mycetoma) when taking Imbruvica *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 0.0 %
  • 50-59: 0.0 %
  • 60+: 100 %

Common drugs people take besides Imbruvica *:

  1. Gliclazide: 3 people, 75.00%
  2. Zydelig: 2 people, 50.00%
  3. Keppra: 2 people, 50.00%

Common side effects people have besides Pulmonary aspergilloma (mycetoma) *:

  1. Rashes (redness): 3 people, 75.00%
  2. Death: 3 people, 75.00%
  3. White Blood Cell Count Increased: 2 people, 50.00%
  4. Head Injury: 2 people, 50.00%
  5. Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 2 people, 50.00%
  6. Ascites (accumulation of fluid in the abdominal cavity): 2 people, 50.00%
  7. Blister (small pocket of fluid within the upper layers of the skin caused by forceful rubbing (friction), burning, freezing, chemical exposure): 2 people, 50.00%
  8. Blood Albumin Decreased: 2 people, 50.00%
  9. Brain Oedema (excess accumulation of fluid in the intracellular or extracellular spaces of the brain): 2 people, 50.00%
  10. Central Nervous System Lesion (an abnormality in tissue of brain or spinal cord): 2 people, 50.00%

Common conditions people have *:

  1. Chronic Lymphocytic Leukaemia (cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell)): 3 people, 75.00%
  2. High Blood Pressure: 1 person, 25.00%
  3. High Blood Cholesterol: 1 person, 25.00%
  4. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 1 person, 25.00%
  5. Diabetes: 1 person, 25.00%
  6. B-Cell Small Lymphocytic Lymphoma (blood cancer affecting b cells): 1 person, 25.00%

* Approximation only. Some reports may have incomplete information.

Do you take Imbruvica and have Pulmonary aspergilloma (mycetoma)?

Check whether Pulmonary aspergilloma (mycetoma) is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

How severe was Pulmonary aspergilloma (mycetoma) and when was it recovered:

Expand to all the drugs that have ingredients of ibrutinib:

Alternative drugs to, pros and cons of Imbruvica:

Common Imbruvica side effects:

Browse all side effects of Imbruvica:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Pulmonary aspergilloma (mycetoma) treatments and more:

COVID vaccines that are related to Pulmonary aspergilloma (mycetoma):

All the drugs that are associated with Pulmonary aspergilloma (mycetoma):

All the conditions that are associated with Pulmonary aspergilloma (mycetoma):

How the study uses the data?

The study uses data from the FDA. It is based on ibrutinib (the active ingredients of Imbruvica) and Imbruvica (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).


WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: